跳至主要内容
临床试验/2025-523650-14-00
2025-523650-14-00招募中2 期

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

Centre Jean Perrin2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2026年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
80
试验地点
2
主要终点
The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands. The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature. A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake. The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.

研究概览

简要总结

to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group: digital osteoarthritis (DOA) and rheumatoid arthritis (RA)

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Both Groups : Karnofsky Index > 70%
  • DOA Group : stopping NSAIDs for at least 8 days
  • Both groups: Obtaining written, signed and dated informed consent
  • Both groups: Affiliation to a health insurance plan
  • Both groups : For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on a GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days prior to injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months without any other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.
  • Both groups : Ability and willingness to comply with clinic visits, tests, and the protocol
  • RA Group : certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR/EULAR criteria
  • RA Group : symptomatic (finger pain > 4 /10 on a numerical scale)
  • RA Group :active synovitis (clinical and ultrasound)
  • DOA Group : certain diagnosis of symptomatic DOA less than 5 years old (finger pain > 4 /10 on a numerical scale)

排除标准

  • Both Groups : Ongoing NSAID usage
  • Both groups : Inability to undergo the trial’s medical follow-up due to geographical, family, social, or psychological reasons. These conditions must be discussed with the patient prior to enrollment in the study.
  • RA Group : Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment
  • RA Group : Patients with a history of hand AD
  • Both groups : Treatment by local joint corticosteroid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5
  • Both groups : History of osteoarticular surgery on the hands
  • Both groups : History of soft tissue surgery on the hands within the past 6 months
  • Both groups : Patients under the age of 18 years old
  • Both groups : Pregnant or breastfeeding patients
  • Both groups : BMI > 30
  • Both groups : History of known allergy to the excipients contained in the 99mTc-NTP 15-5 solution
  • Both groups : Individuals deprived of their liberty, under guardianship/curatorship, or subject to judicial protection

研究组 & 干预措施

99mTc NTP15-5

Test

干预措施: 99mTc NTP15-5 (Drug)

结局指标

主要结局

The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands. The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature. A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake. The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.

The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands. The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature. A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake. The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.

次要结局

  • Performance measures of 99mTc-NTP 15-5 imaging for distinguishing between DAO and RA. Readers will classify the scintigrams as DAO or RA based on the uptake pattern. A consensus will be sought in cases of disagreement. The gold standard will be the diagnosis determined by radioclinical analysis.
  • Performance measures for 99mTc-NTP 15-5 imaging to detect an affected joint complex, including: - For RA: MCP joints of the 2nd–5th fingers and IP joints of the 2nd–5th fingers - For DOA: CMC joints of the 2nd–5th fingers, IP joints of the 2nd–5th fingers, and 1R (CMC, MCP, and IP joints of the 1st finger)
  • The proportion of joints classified as pathological, according to the scintigraphic method and the radiographic-clinical method.
  • Measurements of the radial joint-diaphysis ratio (99mTc-NTP 15-5J/D) determined by semi-automatic tracing of joint interfaces on scintigraphic images and manually traced spherical regions of interest on the radial diaphyses
  • Inter-observer reproducibility measures: Cohen’s kappa coefficient for visual readings (prior to consensus) and ICC for quantitative readings.
  • All skeletal joints other than the hands will be rated by a score identical to that used during phase I: 0: no fixation, 1: fixation < adjacent diaphysis, 2: fixation = adjacent diaphysis, 3: fixation > adjacent diaphysis
  • Adverse events classified according to the NCI-CTCAE V5.0 criteria and associated with 99mTc-NTP 15-5 occurring within one week of injection

研究者

发起方
Centre Jean Perrin
申办方类型
Patient organisation/association
责任方
Principal Investigator
主要研究者

Emilie THIVAT

Scientific

Centre Jean Perrin

研究点 (2)

Loading locations...

相似试验